{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:47:29Z","timestamp":1792115249732,"version":"4.4.0"},"reference-count":149,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"SFB 1181","award":["B02"],"award-info":[{"award-number":["B02"]}]},{"name":"SFB 1181","award":["316213987"],"award-info":[{"award-number":["316213987"]}]},{"name":"SFB 1181","award":["B03"],"award-info":[{"award-number":["B03"]}]},{"name":"DFG, German Research Foundation","award":["B02"],"award-info":[{"award-number":["B02"]}]},{"name":"DFG, German Research Foundation","award":["316213987"],"award-info":[{"award-number":["316213987"]}]},{"name":"DFG, German Research Foundation","award":["B03"],"award-info":[{"award-number":["B03"]}]},{"name":"SFB 1278","award":["B02"],"award-info":[{"award-number":["B02"]}]},{"name":"SFB 1278","award":["316213987"],"award-info":[{"award-number":["316213987"]}]},{"name":"SFB 1278","award":["B03"],"award-info":[{"award-number":["B03"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The mechanism of RNA interference (RNAi) could represent a breakthrough in the therapy of all diseases that arise from a gene defect or require the inhibition of a specific gene expression. In particular, small interfering RNA (siRNA) offers an attractive opportunity to achieve a new milestone in the therapy of human diseases. The limitations of siRNA, such as poor stability, inefficient cell uptake, and undesired immune activation, as well as the inability to specifically reach the target tissue in the body, can be overcome by further developments in the field of nanoparticulate drug delivery. Therefore, types of surface modified siRNA nanoparticles are presented and illustrate how a more efficient and safer distribution of siRNA at the target site is possible by modifying the surface properties of nanoparticles with antibodies. However, the development of such efficient and safe delivery strategies is currently still a major challenge. In consideration of that, this review article aims to demonstrate the function and targeted delivery of siRNA nanoparticles, focusing on the surface modification via antibodies, various lipid- and polymer-components, and the therapeutic effects of these delivery systems.<\/jats:p>","DOI":"10.3390\/ijms232213929","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T02:29:32Z","timestamp":1668392972000},"page":"13929","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies"],"prefix":"10.3390","volume":"23","author":[{"given":"Michael","family":"Gabel","sequence":"first","affiliation":[{"name":"Medical Clinic I, Research Campus, University Hospital of Erlangen, Hartmannstra\u00dfe 14, 91052 Erlangen, Germany"},{"name":"Medical Immunology Campus Erlangen, Medical Clinic 1, Friedrich-Alexander University Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annkathrin","family":"Knauss","sequence":"additional","affiliation":[{"name":"Medical Clinic I, Research Campus, University Hospital of Erlangen, Hartmannstra\u00dfe 14, 91052 Erlangen, Germany"},{"name":"Medical Immunology Campus Erlangen, Medical Clinic 1, Friedrich-Alexander University Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Pharmacy, Division of Pharmaceutical Technology and Biopharmacy, Friedrich-Alexander University Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus F.","family":"Neurath","sequence":"additional","affiliation":[{"name":"Medical Clinic I, University Hospital Erlangen, Ulmenweg 18, 91054 Erlangen, Germany"},{"name":"Deutsches Zentrum Immuntherapie (DZI), 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2398-0844","authenticated-orcid":false,"given":"Benno","family":"Weigmann","sequence":"additional","affiliation":[{"name":"Medical Clinic I, Research Campus, University Hospital of Erlangen, Hartmannstra\u00dfe 14, 91052 Erlangen, Germany"},{"name":"Medical Immunology Campus Erlangen, Medical Clinic 1, Friedrich-Alexander University Erlangen-N\u00fcrnberg, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biotechadv.2019.04.012","article-title":"RNAi therapeutic and its innovative biotechnological evolution","volume":"37","author":"Weng","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2307\/3869076","article-title":"Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in Trans","volume":"2","author":"Napoli","year":"1990","journal-title":"Plant Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1365-313X.1994.6060861.x","article-title":"Transgene-Mediated Suppression of Chalcone Synthase Expression in Petunia-Hybrida Results from an Increase in Rna Turnover","volume":"6","author":"Vanblokland","year":"1994","journal-title":"Plant J."},{"key":"ref_5","first-page":"2849","article-title":"The Nobel Prize in Physiology or Medicine for 2006 for the discovery of RNA interference","volume":"150","author":"Bernards","year":"2006","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: State of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","article-title":"Strategies, design, and chemistry in siRNA delivery systems","volume":"144","author":"Dong","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.exger.2004.03.040","article-title":"RNAi: Ancient mechanism with a promising future","volume":"39","author":"Geley","year":"2004","journal-title":"Exp. Gerontol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"587012","DOI":"10.3389\/fmolb.2020.587012","article-title":"Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization","volume":"7","author":"Sanita","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","article-title":"Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases","volume":"94","author":"Schoch","year":"2017","journal-title":"Neuron"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"107534","DOI":"10.1016\/j.biotechadv.2020.107534","article-title":"The challenge and prospect of mRNA therapeutics landscape","volume":"40","author":"Weng","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/nbt.3298","article-title":"Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown","volume":"33","author":"Wittrup","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_16","first-page":"292","article-title":"Delivery of therapeutic oligonucleotides in nanoscale","volume":"7","author":"Wu","year":"2022","journal-title":"Bioact. Mater."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.addr.2015.12.004","article-title":"Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines","volume":"104","author":"Park","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/17435889.3.5.703","article-title":"Clearance properties of nano-sized particles and molecules as imaging agents: Considerations and caveats","volume":"3","author":"Longmire","year":"2008","journal-title":"Nanomedicine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrg3978","article-title":"Knocking down disease: A progress report on siRNA therapeutics","volume":"16","author":"Wittrup","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol.."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1039\/b920362c","article-title":"RNA interference: A chemist\u2019s perspective","volume":"39","author":"Gaynor","year":"2010","journal-title":"Chem. Soc. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/35053110","article-title":"Role for a bidentate ribonuclease in the initiation step of RNA interference","volume":"409","author":"Bernstein","year":"2001","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/wrna.1356","article-title":"Anatomy of RISC: How do small RNAs and chaperones activate Argonaute proteins?","volume":"7","author":"Nakanishi","year":"2016","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","article-title":"Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways","volume":"441","author":"Grimm","year":"2006","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"14385","DOI":"10.1073\/pnas.0405913101","article-title":"Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity","volume":"101","author":"Rand","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA Versus miRNA as Therapeutics for Gene Silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther.-Nucl. Acids"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1126\/science.1073827","article-title":"A microRNA in a multiple-turnover RNAi enzyme complex","volume":"297","author":"Hutvagner","year":"2002","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/nar\/gkj439","article-title":"Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging","volume":"34","author":"Bartlett","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm1191","article-title":"Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7","volume":"11","author":"Hornung","year":"2005","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1073\/pnas.0812317106","article-title":"Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth","volume":"106","author":"Cho","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1073\/pnas.0308698100","article-title":"Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells","volume":"101","author":"Scacheri","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nbt831","article-title":"Expression profiling reveals off-target gene regulation by RNAi","volume":"21","author":"Jackson","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1080\/15476286.2020.1868680","article-title":"Off-target effects of RNAi correlate with the mismatch rate between dsRNA and non-target mRNA","volume":"18","author":"Chen","year":"2021","journal-title":"Rna Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s11658-019-0196-3","article-title":"Editorial focus: Understanding off-target effects as the key to successful RNAi therapy","volume":"24","author":"Bartoszewski","year":"2019","journal-title":"Cell Mol. Biol. Lett."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1093\/nar\/gku480","article-title":"siPools: Highly complex but accurately defined siRNA pools eliminate off-target effects","volume":"42","author":"Hannus","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_37","first-page":"570","article-title":"FDA approves patisiran to treat hereditary transthyretin amyloidosis","volume":"14","author":"Wood","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: First Approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: First Approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/13543784.2018.1457647","article-title":"Tivanisiran, a novel siRNA for the treatment of dry eye disease","volume":"27","author":"Bleau","year":"2018","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"114432","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: Updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1900085","DOI":"10.1002\/mabi.201900085","article-title":"Amino Acid-Substituted Dextran-Based Non-Viral Vectors for Gene Delivery","volume":"19","author":"Zink","year":"2019","journal-title":"Macromol. Biosci."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Nasr, S.S., Lee, S., Thiyagarajan, D., Boese, A., Loretz, B., and Lehr, C.M. (2021). Co-Delivery of mRNA and pDNA Using Thermally Stabilized Coacervate-Based Core-Shell Nanosystems. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111924"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Friedrich, B., Auger, J.P., Dutz, S., Cicha, I., Schreiber, E., Band, J., Boccacccini, A.R., Kronke, G., Alexiou, C., and Tietze, R. (2021). Hydroxyapatite-Coated SPIONs and Their Influence on Cytokine Release. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084143"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e1903637","DOI":"10.1002\/adma.201903637","article-title":"Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery","volume":"31","author":"Kim","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jconrel.2011.11.014","article-title":"Therapeutic plasmid DNA versus siRNA delivery: Common and different tasks for synthetic carriers","volume":"161","author":"Scholz","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.drudis.2008.05.007","article-title":"Chemically modified siRNA: Tools and applications","volume":"13","author":"Watts","year":"2008","journal-title":"Drug. Discov. Today"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1021\/mp9000124","article-title":"Synthesis and Biological Evaluation of a Bioresponsive and Endosomolytic siRNA-Polymer Conjugate","volume":"6","author":"Meyer","year":"2009","journal-title":"Mol. Pharmaceut."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/1061186X.2018.1502775","article-title":"Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex","volume":"27","author":"Hattori","year":"2019","journal-title":"J. Drug Target."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s13346-020-00723-6","article-title":"Nanostructured lipid carrier co-delivering tacrolimus and TNF-\u03b1 siRNA as an innovate approach to psoriasis","volume":"10","author":"Viegas","year":"2020","journal-title":"Drug Deliv. Transl Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Francis, J.E., Skakic, I., Dekiwadia, C., Shukla, R., Taki, A.C., Walduck, A., and Smooker, P.M. (2020). Solid Lipid Nanoparticle Carrier Platform Containing Synthetic TLR4 Agonist Mediates Non-Viral DNA Vaccine Delivery. Vaccines, 8.","DOI":"10.3390\/vaccines8030551"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid Nanoparticles-From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"Acs Nano."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nmat3765","article-title":"Delivery materials for siRNA therapeutics","volume":"12","author":"Kanasty","year":"2013","journal-title":"Nat. Mater."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.addr.2020.07.022","article-title":"Recent advances in siRNA delivery mediated by lipid-based nanoparticles","volume":"154","author":"Yonezawa","year":"2020","journal-title":"Adv. Drug Deliver. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41578-021-00400-1","article-title":"Lipid nanoparticles for mRNA delivery (Aug, 10.\/s41578\u2013021\u201300358\u20130, 2021)","volume":"7","author":"Hou","year":"2022","journal-title":"Nat. Rev. Mater."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"120772","DOI":"10.1016\/j.ijpharm.2021.120772","article-title":"Cationic lipid nanoparticle production by microfluidization for siRNA delivery","volume":"605","author":"Liu","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_58","first-page":"62","article-title":"Strategies to overcome the polycation dilemma in drug delivery","volume":"136","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0005-2736(00)00343-6","article-title":"Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: Formation of novel small multilamellar vesicle structures","volume":"1510","author":"Semple","year":"2001","journal-title":"Bba-Biomembranes."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1038\/mtna.2012.28","article-title":"Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA","volume":"1","author":"Belliveau","year":"2012","journal-title":"Mol.-Nucl Acids."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0169-409X(01)00103-X","article-title":"Roles of lipid polymorphism in intracellular delivery","volume":"47","author":"Hafez","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.nano.2016.12.014","article-title":"Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA","volume":"13","author":"Kulkarni","year":"2017","journal-title":"Nanomed.-Nanotechnol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"21733","DOI":"10.1039\/C9NR09347H","article-title":"On the role of helper lipids in lipid nanoparticle formulations of siRNA","volume":"11","author":"Kulkarni","year":"2019","journal-title":"Nanoscale"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13346-015-0220-8","article-title":"Influence of cholesterol on liposome stability and on in vitro drug release","volume":"5","author":"Briuglia","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.bpj.2018.10.024","article-title":"Spatially Resolving the Condensing Effect of Cholesterol in Lipid Bilayers","volume":"115","author":"Leeb","year":"2018","journal-title":"Biophys. J."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0005-2795(79)90111-9","article-title":"Preparation of a Non-Immunogenic Arginase by the Covalent Attachment of Polyethylene-Glycol","volume":"578","author":"Savoca","year":"1979","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/polym12020298","article-title":"The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation","volume":"12","author":"Thi","year":"2020","journal-title":"Polymers"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-9092-4_22","article-title":"Anti-PEG IgM Production via a PEGylated Nanocarrier System for Nucleic Acid Delivery","volume":"1943","author":"Ishida","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.chembiol.2019.02.001","article-title":"Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers","volume":"26","author":"Moreno","year":"2019","journal-title":"Cell Chem. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.colsurfb.2017.04.018","article-title":"Interaction between PEG lipid and DSPE\/DSPC phospholipids: An insight of PEGylation degree and kinetics of de-PEGylation","volume":"155","author":"Paolino","year":"2017","journal-title":"Colloid Surf. B"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10832","DOI":"10.1039\/C6NR02174C","article-title":"\u201cSheddable\u201d PEG-lipid to balance the contradiction of PEGylation between long circulation and poor uptake","volume":"8","author":"Zhao","year":"2016","journal-title":"Nanoscale"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/mtna.2013.66","article-title":"Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther.-Nucl. Acids"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e1704039","DOI":"10.1002\/smll.201704039","article-title":"Liposome Crosslinked Polyacrylamide\/DNA Hydrogel: A Smart Controlled-Release System for Small Molecular Payloads","volume":"14","author":"Lyu","year":"2018","journal-title":"Small"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Azevedo, H.S., Mano, J.F., and Borges, J. (2021). Liposomes for Biomedical Applications, Royal Society of Chemistry. Soft Matter Series.","DOI":"10.1039\/9781839161124"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Shetab Boushehri, M.A., Dietrich, D., and Lamprecht, A. (2020). Nanotechnology as a Platform for the Development of Injectable Parenteral Formulations: A Comprehensive Review of the Know-Hows and State of the Art. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060510"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jconrel.2014.03.039","article-title":"Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases","volume":"183","author":"Ali","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40005-017-0320-1","article-title":"Mechanisms of drug release from advanced drug formulations such as polymeric-based drug-delivery systems and lipid nanoparticles","volume":"47","author":"Son","year":"2017","journal-title":"J. Pharm. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"109191","DOI":"10.1016\/j.eurpolymj.2019.08.018","article-title":"Biodegradable polymers and constructs: A novel approach in drug delivery","volume":"120","author":"Prajapati","year":"2019","journal-title":"Eur. Polym. J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.3109\/10717544.2015.1126769","article-title":"EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer","volume":"23","author":"Zhang","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1080\/10717544.2018.1461957","article-title":"Preparation of poly-L-lysine-based nanoparticles with pH-sensitive release of curcumin for targeted imaging and therapy of liver cancer in vitro and in vivo","volume":"25","author":"Yang","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.colsurfb.2019.02.024","article-title":"Curcumin-loaded PLA-PEG copolymer nanoparticles for treatment of liver inflammation in streptozotocin-induced diabetic rats","volume":"177","author":"Anwar","year":"2019","journal-title":"Colloid Surf. B"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1900668","DOI":"10.1002\/marc.201900668","article-title":"Incorporation of Indole Significantly Improves the Transfection Efficiency of Guanidinium-Containing Poly(Methacrylamide)s","volume":"41","author":"Cokca","year":"2020","journal-title":"Macromol. Rapid. Comm."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"BSR20170122","DOI":"10.1042\/BSR20170122","article-title":"Chitosan nanoparticle-delivered siRNA reduces CXCR4 expression and sensitizes breast cancer cells to cisplatin","volume":"37","author":"Yu","year":"2017","journal-title":"Biosci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2002577","DOI":"10.1002\/advs.202002577","article-title":"Modularly Programmable Nanoparticle Vaccine Based on Polyethyleneimine for Personalized Cancer Immunotherapy","volume":"8","author":"Nam","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejpb.2021.11.003","article-title":"Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model","volume":"169","author":"Mendonca","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"8509","DOI":"10.1038\/srep08509","article-title":"MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer","volume":"5","author":"Yang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_87","first-page":"1955","article-title":"Gelatin nanoparticle-mediated intranasal delivery of substance P protects against 6-hydroxydopamine-induced apoptosis: An in vitro and in vivo study","volume":"9","author":"Lu","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Lee, S., and Lee, K. (2020). pH-Sensitive Folic Acid Conjugated Alginate Nanoparticle for Induction of Cancer-Specific Fluorescence Imaging. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060537"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/10717544.2018.1450910","article-title":"Application of hyaluronic acid as carriers in drug delivery","volume":"25","author":"Huang","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Boisguerin, P., Konate, K., Josse, E., Vives, E., and Deshayes, S. (2021). Peptide-Based Nanoparticles for Therapeutic Nucleic Acid Delivery. Biomedicines, 9.","DOI":"10.3390\/biomedicines9050583"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s10570-018-1664-z","article-title":"Polyelectrolyte layer assembly of bacterial nanocellulose whiskers with plasmid DNA as biocompatible non-viral gene delivery system","volume":"25","author":"Potzinger","year":"2018","journal-title":"Cellulose"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.2147\/IJN.S321329","article-title":"Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles","volume":"16","author":"Piperno","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Idrees, H., Zaidi, S.Z.J., Sabir, A., Khan, R.U., Zhang, X.L., and Hassan, S.U. (2020). A Review of Biodegradable Natural Polymer-Based Nanoparticles for Drug Delivery Applications. Nanomaterials, 10.","DOI":"10.3390\/nano10101970"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejps.2003.10.001","article-title":"Biocompatibility and integrin-mediated adhesion of human osteoblasts to poly(DL-lactide-co-glycolide) copolymers","volume":"21","author":"Betti","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejpb.2010.11.008","article-title":"High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: Quality by design optimization and characterization","volume":"77","author":"Cun","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s13239-021-00518-x","article-title":"Delivery of siRNA to Endothelial Cells In Vivo Using Lysine\/Histidine Oligopeptide-Modified Poly(beta-amino ester) Nanoparticles","volume":"12","author":"Dosta","year":"2021","journal-title":"Cardiovasc. Eng. Technol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1124\/jpet.119.256909","article-title":"Effectiveness of Small Interfering RNA Delivery via Arginine-Rich Polyethylenimine-Based Polyplex in Metastatic and Doxorubicin-Resistant Breast Cancer Cells","volume":"370","author":"Lu","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s13346-016-0306-y","article-title":"Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model","volume":"7","author":"Ewe","year":"2017","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.7150\/thno.20297","article-title":"The pH-Triggered Triblock Nanocarrier Enabled Highly Efficient siRNA Delivery for Cancer Therapy","volume":"7","author":"Du","year":"2017","journal-title":"Theranostics"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e1903277","DOI":"10.1002\/adma.201903277","article-title":"ROS-Responsive Polymeric siRNA Nanomedicine Stabilized by Triple Interactions for the Robust Glioblastoma Combinational RNAi Therapy","volume":"31","author":"Zheng","year":"2019","journal-title":"Adv. Mater."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/gt.2014.97","article-title":"Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors","volume":"22","author":"Essex","year":"2015","journal-title":"Gene Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0169-409X(95)00026-4","article-title":"The Controlled Intravenous Delivery of Drugs Using Peg-Coated Sterically Stabilized Nanospheres","volume":"16","author":"Gref","year":"1995","journal-title":"Adv. Drug Delivery Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s12274-020-2655-6","article-title":"The enhanced permeability and retention effect based nanomedicine at the site of injury","volume":"13","author":"Liu","year":"2020","journal-title":"Nano Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s10529-020-02867-4","article-title":"PEG modification enhances the in vivo stability of bioactive proteins immobilized on magnetic nanoparticles","volume":"42","author":"Xu","year":"2020","journal-title":"Biotechnol. Lett."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jconrel.2018.05.035","article-title":"Lipid nanoparticles with minimum burst release of TNF-alpha siRNA show strong activity against rheumatoid arthritis unresponsive to methotrexate","volume":"283","author":"Aldayel","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1021\/acsami.9b21214","article-title":"Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA\/miRNA Combination Cancer Therapy","volume":"12","author":"Wang","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1515\/cdbme-2021-2042","article-title":"Investigation of Inertial Cavitation of Sonosensitive and Biocompatible Nanoparticles in Flow-Through Tissue-Mimicking Phantoms Employing Focused Ultrasound","volume":"7","author":"George","year":"2021","journal-title":"Curr. Dir. Biomed. Eng."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1038\/s41598-021-90585-w","article-title":"Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro","volume":"11","author":"Dunne","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1021\/acs.nanolett.8b01101","article-title":"Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA","volume":"18","author":"Ball","year":"2018","journal-title":"Nano Lett."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s42003-020-0817-4","article-title":"pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics","volume":"3","author":"Palanikumar","year":"2020","journal-title":"Commun. Biol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1038\/ncomms6565","article-title":"Cell type-specific delivery of short interfering RNAs by dye-functionalised theranostic nanoparticles","volume":"5","author":"Press","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1038\/s41467-021-23250-5","article-title":"Programmably tiling rigidified DNA brick on gold nanoparticle as multi-functional shell for cancer-targeted delivery of siRNAs","volume":"12","author":"Xue","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_113","first-page":"2061","article-title":"Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models","volume":"288","author":"Kiani","year":"2022","journal-title":"Life Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jconrel.2020.10.022","article-title":"Hyaluronate siRNA nanoparticles with positive charge display rapid attachment to tumor endothelium and penetration into tumors","volume":"329","author":"Luo","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"15501","DOI":"10.1021\/ja406406h","article-title":"Phenylboronic Acid-Installed Polymeric Micelles for Targeting Sialylated Epitopes in Solid Tumors","volume":"135","author":"Deshayes","year":"2013","journal-title":"J. Am. Chem. Soc."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12951-022-01377-x","article-title":"Multifunctional nanoparticles co-loaded with Adriamycin and MDR-targeting siRNAs for treatment of chemotherapy-resistant esophageal cancer","volume":"20","author":"Zhang","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/nm.2472","article-title":"Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: First in-human results","volume":"17","author":"Themelis","year":"2011","journal-title":"Nat. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1039\/C7NR08644J","article-title":"Enhanced delivery of siRNA to triple negative breast cancer cells in vitro and in vivo through functionalizing lipid-coated calcium phosphate nanoparticles with dual target ligands","volume":"10","author":"Tang","year":"2018","journal-title":"Nanoscale"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"15549","DOI":"10.1073\/pnas.0707461104","article-title":"Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging","volume":"104","author":"Bartlett","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1073\/pnas.0914140107","article-title":"Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles","volume":"107","author":"Choi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Chiu, M.L., Goulet, D.R., Teplyakov, A., and Gilliland, G.L. (2019). Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies, 8.","DOI":"10.3390\/antib8040055"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nri1266","article-title":"Human antibody-Fc receptor interactions illuminated by crystal structures","volume":"4","author":"Woof","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/264415a0","article-title":"Crystallographic structure studies of an IgG molecule and an Fc fragment","volume":"264","author":"Huber","year":"1976","journal-title":"Nature"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/imr.12385","article-title":"Engineered IgG1-Fc--one fragment to bind them all","volume":"270","author":"Lobner","year":"2016","journal-title":"Immunol. Rev."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1039\/C6SC02403C","article-title":"Antibody fragments as nanoparticle targeting ligands: A step in the right direction","volume":"8","author":"Richards","year":"2017","journal-title":"Chem. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-62703-550-7_11","article-title":"Tips for the functionalization of nanoparticles with antibodies","volume":"1051","author":"Polo","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"13859","DOI":"10.1038\/s41598-019-50424-5","article-title":"Impact of conjugation strategies for targeting of antibodies in gold nanoparticles for ultrasensitive detection of 17beta-estradiol","volume":"9","author":"Oliveira","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_129","unstructured":"Prieto, J.P., and B\u00e9jar, M.G. (2019). Chapter 9\u2014State-Of-The-Art Strategies for the Biofunctionalization of Photoactive Inorganic Nanoparticles for Nanomedicine. Photoactive Inorganic Nanoparticles, Elsevier."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jconrel.2020.01.035","article-title":"Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies","volume":"320","author":"Marques","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA-Cancer J. Clin."},{"key":"ref_132","first-page":"17","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Alatab","year":"2020","journal-title":"Lancet Gastroenterol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41551-021-00698-w","article-title":"The evolution of commercial drug delivery technologies","volume":"5","author":"Vargason","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0092-8674(90)90694-A","article-title":"Cd44 Is the Principal Cell-Surface Receptor for Hyaluronate","volume":"61","author":"Aruffo","year":"1990","journal-title":"Cell"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000011970","article-title":"Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer","volume":"56","author":"Yamane","year":"1999","journal-title":"Oncolpgy"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1900018","DOI":"10.1002\/adfm.201900018","article-title":"Binary Targeting of siRNA to Hematologic Cancer Cells In Vivo Using Layer-by-Layer Nanoparticles","volume":"29","author":"Choi","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acs.molpharmaceut.6b01150","article-title":"Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy","volume":"14","author":"Guo","year":"2017","journal-title":"Mol. Pharmaceut."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2147\/IJN.S340926","article-title":"Dual pH-Responsive and Tumor-Targeted Nanoparticle-Mediated Anti-Angiogenesis siRNA Delivery for Tumor Treatment","volume":"17","author":"Zhang","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1053\/j.gastro.2014.01.056","article-title":"Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice","volume":"146","author":"Xiao","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jconrel.2021.07.034","article-title":"Therapeutic inhibitory RNA in head and neck cancer via functional targeted lipid nanoparticles","volume":"337","author":"Kampel","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10147-016-1005-x","article-title":"The molecular mechanism of human papillomavirus-induced carcinogenesis in head and neck squamous cell carcinoma","volume":"21","author":"Sano","year":"2016","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2006.06.7447","article-title":"Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy","volume":"25","author":"Vermorken","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41565-017-0043-5","article-title":"A modular platform for targeted RNAi therapeutics","volume":"13","author":"Kedmi","year":"2018","journal-title":"Nat. Nanotechnol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1016\/j.xphs.2020.05.018","article-title":"Delivery of TSPAN1 siRNA by Novel Th17 Targeted Cationic Liposomes for Gastric Cancer Intervention","volume":"109","author":"Lu","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jss.2012.07.055","article-title":"Prevalence and clinical relevance of Th17 cells in patients with gastric cancer","volume":"178","author":"Yamada","year":"2012","journal-title":"J. Surg. Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3748\/wjg.15.2270","article-title":"TSPAN1 protein expression: A significant prognostic indicator for patients with colorectal adenocarcinoma","volume":"15","author":"Chen","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/cgt.2015.18","article-title":"Inhibition of pulmonary cancer progression by epidermal growth factor receptor-targeted transfection with Bcl-2 and survivin siRNAs","volume":"22","author":"Lee","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jconrel.2019.10.001","article-title":"Leukocyte-specific siRNA delivery revealing IRF8 as a potential anti-inflammatory target","volume":"313","author":"Veiga","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4049\/jimmunol.168.1.411","article-title":"Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA","volume":"168","author":"Wirtz","year":"2002","journal-title":"J. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/22\/13929\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:16:39Z","timestamp":1760145399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/22\/13929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":149,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["ijms232213929"],"URL":"https:\/\/doi.org\/10.3390\/ijms232213929","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]}}}